|
WO2020251017A1
|
|
Composition for external application
|
|
CN112020366A
|
|
Pharmaceutical composition containing dipeptide
|
|
CN112041328A
|
|
Dipeptide and pharmaceutical composition containing the same
|
|
WO2018155525A1
|
|
Anti-inflammatory agent
|
|
JP2018158890A
|
|
Sterilization compositions
|
|
JP2018015434A
|
|
Joint supporter
|
|
JP2019167295A
|
|
Method for producing calcium salt of 1, 5-benzodiazepine compound
|
|
JP2017002045A
|
|
Orally disintegrating tablet
|
|
JP2019131467A
|
|
Crystal of 1,5-benzodiazepine compound
|
|
JP2016216441A
|
|
Liquid agent for internal use
|
|
CN107073043A
|
|
Illness behavior condition improver
|
|
CN105579049A
|
|
Liver function and/or pancreatic function improving agent
|
|
KR20160041916A
|
|
Amp-activated protein kinase activator
|
|
EP2979702A1
|
|
Postprandial gastrokinetic agent
|
|
AU2011244991A1
|
|
Method for producing aminothiazole derivative and production intermediate
|
|
AU2011244994A1
|
|
Method for producing aminothiazole derivative and production intermediate
|
|
AU2011244996A1
|
|
Method for producing aminothiazole derivative and production intermediate
|
|
JP2013095670A
|
|
Carbonic acid-containing internal liquid preparation
|
|
JP2013082644A
|
|
Oral liquid medicine composition
|
|
JP2013079199A
|
|
Constipation-improving drug
|
